检索结果-南通市图书馆

Unraveling brain aging through the lens of oral microbiota

Neural Regeneration research 2025年第7期20卷 1930-1943页

作者： Qinchao Hu Si Wang Weiqi Zhang Jing Qu Guang-Hui Liu State Key laboratory of Membrane Biology Institute of ZoologyChinese Academy of SciencesBeijingChina Hospital of Stomatology Guanghua School of StomatologyGuangdong Provincial Key Laboratory of StomatologySun Yat-sen UniversityGuangzhouGuangdong ProvinceChina Advanced Innovation Center for Human Brain Protection and National Clinical research Center for Geriatric Disorders Xuanwu HospitalCapital Medical UniversityBeijingChina Aging translational Medicine Center International Center for Aging and CancerBeijing Municipal Geriatric Medical Research CenterXuanwu HospitalCapital Medical UniversityBeijingChina CAS Key laboratory of genomic and Precision Medicine Beijing Institute of GenomicsChinese Academy of Sciences and China National Center for BioinformationBeijingChina University of Chinese Academy of Sciences BeijingChina Institute for Stem Cell and Regeneration Chinese Academy of SciencesBeijingChina Aging Biomarker Consortium BeijingChina State Key laboratory of Stem Cell and Reproductive Biology Institute of ZoologyChinese Academy of SciencesBeijingChina Beijing Institute for Stem Cell and Regenerative Medicine BeijingChina

The oral cavity is a complex physiological community encompassing a wide range of *** of oral microbiota can lead to various oral infectious diseases,such as periodontitis and tooth decay,and even affect systemic health,including brain aging and neurodegenerative *** studies have highlighted how oral microbes might be involved in brain aging and neurodegeneration,indicating potential avenues for intervention *** this review,we summarize clinical evidence demonstrating a link between oral microbes/oral infectious diseases and brain aging/neurodegenerative diseases,and dissect potential mechanisms by which oral microbes contribute to brain aging and *** also highlight advances in therapeutic development grounded in the realm of oral microbes,with the goal of advancing brain health and promoting healthy aging.

关键词： Alzheimer's disease brain aging multiple sclerosis neurodegeneration neurodegenerative diseases oral microbiota Parkinson's disease periodontitis bacteria Porphyromonas gingivalis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trial

引用

Science China Life Sciences 2025年第1期68卷 249-262页

作者： Jinliang Wang Wenyong Zhou Yu Xu Jianchun Duan Qiaoxia Zhou Guoqiang Wang Leo Li Chunwei Xu Wenxian Wang Shangli Cai Zhijie Wang Jie Wang Department of Oncology The Fifth Medical Center of Chinese PLA General Hospital Department of Thoracic Surgery Shanghai Chest HospitalSchool of MedicineShanghai Jiao Tong University Burning Rock Biotech CAMS Key laboratory of translational research on Lung Cancer State Key Laboratory of Molecular OncologyDepartment of Medical OncologyNational Cancer Center/National Clinical Research Center for ancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical College Institute of Basic Medicine and Cancer (IBMC) Chinese Academy of Sciences Department of Clinical Trial The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

In non-small cell lung cancers,the non-squamous and squamous subtypes（nsqNSCLC and sqNSCLC） exhibit disparities in pathophysiology,tumor immunology,and potential genomic correlates affecting responses to immune checkpoint inhibitor（ICI）-based *** our inhouse training cohort（n=85）,the presence of the LRP1B deleterious mutation（LRP1B-del） was associated with longer and shorter progression-free survival（PFS） on ICIs alone in nsqNSCLCs and sqNSCLCs,respectively(Pinteraction=0.008).These results were validated using a larger public ICI cohort(n=208,Pinteraction<0.001).Multiplex immunofluorescence staining revealed an association between LRP1B-del and increased and decreased numbers of tumor-infiltrating CD8+T cells in nsqNSCLCs（P=0.040） and sqNSCLCs（P=0.014）,*** the POPLAR/OAK cohort,nsqNSCLCs with LRP1B-del demonstrated improved PFS benefits from atezolizumab over docetaxel(hazard ratio（HR）=0.70,P=0.046),whereas this benefit was negligible in those without LRP1B-del（HR=1.05,P=0.64）.Conversely,sqNSCLCs without LRP1B-del benefited more from atezolizumab（HR=0.60,P=0.002） than those with LRP1B-del（HR=1.30,P=0.31）.Consistent results were observed in the in-house CHOICE-01 cohort,in which nsqNSCLCs with LRP1B-del and sqNSCLCs without LRP1B-del benefited more from toripalimab plus chemotherapy than from chemotherapy alone(Pinteraction=0.008).This multi-cohort study delineates the antithetical impacts of LRP1B-del in nsqNSCLCs and sqNSCLCs on predicting the benefits from ICI alone or with chemotherapy over chemotherapy *** findings highlight the distinct clinical utility of LRP1B-del in guiding treatment choices for nsqNSCLCs and sqNSCLCs,emphasizing the necessity for a detailed analysis based on pathological subtypes when investigating biomarkers for cancer therapeutics.

关键词： non-squamous NSCLC squamous NSCLC LRP1B deleterious mutations predictive biomarker immune checkpoint inhibitor

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Primary gastrointestinal mantle lymphoma with massive bleeding: a case report and literature review

引用

Chinese Journal of Cancer research 2013年第2期25卷 250-253页

作者： Wen Zheng Yuqin Song Ningjing Lin Meifeng Tu Weiping Liu Jun Zhu Key laboratory of Carcinogenesis and translational research (Ministry of Education) Department of Lymphoma Peking University Cancer Hospital & Institute

The incidence of primary gastrointestinal lymphomas （PGILs） has been increasing. The clinical presentation and treatment of PGIL are distinct from those of nodular lymphomas. Symptoms include abdominal pain, abdominal mass, changes in bowel habits, obstruction, and bleeding. Less life- threatening gastrointestinal bleeding occurs after chemotherapy and few reports have focused on the bleeding of PGILs. We report a case of severe gastrointestinal bleeding caused by low-dose chemotherapy, which was dramatically improved by rituximab monotherapy treatment. The prevention and treatment of gastrointestinal bleeding in PGIL should be given much attention.

关键词： Gastrointestinal tract mantle lymphoma bleeding

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Prognostic value of interim ^(18)F-FDG PET/CT in diffuse large B-cell lymphoma

引用

Chinese Journal of Cancer research 2013年第1期25卷 95-101页

作者： Zhitao Ying Xuejuan Wang Yuqin Song Wen Zheng Xiaopei Wang Yan Xie Ningjing Lin Meifeng Tu Lingyan Ping Weiping Liu Lijuan Deng Chen Zhang Zhi Yang Jun Zhu Key laboratory of Carcinogenesis and translational research (Ministry of Education) Department of LymphomaPeking University Cancer Hospital & Institute Key laboratory of Carcinogenesis and translational research (Ministry of Education) Department of Nuclear MedicinePeking University Cancer Hospital & Institute

Objective： Diffuse large B-cell lymphoma （DLBCL） is a heterogeneous disease. The prognostic factor currently used is not accurate enough to predict the outcomes of patients with DLBCL. The prognostic significance of interim PET/CT in DLBCL remains controversial. The aim of this study is to determine the predictive value of interim 18F-FDG PET/CT after first-line treatment in patients with DLBCL. Methods： Thirty-two patients with DLBCL underwent baseline, interim and post-treatment lSF-FDG PET/CT scans. Imaging results were analyzed for the survival of patients via software SPSS 13.0, retrospectively. Results： Thirty-one of the 32 patients were treated with R-CHOP regimen, and interim 18F-FDG PET/CT of 24 patients was performed after 2 cycles of treatment. After a median follow-up period of 16.7 months, the 2-year progression-free survival （PFS） rates were significantly different between the groups above and below SUVmax CUt-Off value of 2.5 （P=0.039）. No significant differences were found in the 2-year PFS rates if SUVm, cut-offvalues were set as 2.0 and 3.0, respectively （P=0.360; P=0.113）. Conclusions： Interim PET/CT could predict the prognosis of DLBCL patients with the SUVmax cut-off value of 2.5, but more clinical data should be concluded to confirm this conclusion.

关键词： Fludeoxy-glucose F18 lyrnphoma large cell diffuse prognosis standard utility value

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Comments on Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018(English version)

引用

Chinese Journal of Cancer research 2019年第5期31卷 738-739页

作者： Weiping Liu Jun Zhu Key laboratory of Carcinogenesis and translational research (Ministry of Education/Beijing) Department of Lymphoma Peking University Cancer Hospital & Institute

Lymphoid and myeloid neoplasms are common malignant tumors in China,which threaten people’s health(1).To improve the diagnosis and treatment of lymphoma,the National Health Commission of the People’s Republic of China revised Chinese guidelines for diagnosis and treatment of malignant lymphoma in 2018(2).The new guidelines are based on the Classification of Tumours of Haematopoietic and Lymphoid Tissues revised by the World Health Organization in *** new edition provided principles of accurate pathological diagnosis of lymphoma on the basis of various scales including histomorphology,immunohistochemistry,fluorescent immunohybridization and genetics.

关键词： diagnosis neoplasms treatment

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab:A case report

引用

World Journal of Clinical Cases 2021年第21期9卷 6041-6048页

作者： Xiao-Sheng Ding Lan Mi Yu-Qin Song Wei-Ping Liu Hui Yu Ning-Jing Lin Jun Zhu Department of lymphoma Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital&InstituteBeijing 100142China

BACKGROUND Academic studies have proved that anti-programmed death-1(PD-1)monoclonal antibodies demonstrated remarkable activity in relapsed/refractory classical Hodgkin lymphoma(cHL).However,most patients ultimately experienced failure or *** is urgent and necessary to develop a novel strategy for relapsed/refractory *** aim of this case report is to evaluate the combination approach of low-dose decitabine plus a PD-1 inhibitor in relapsed/refractory cHL patients with prior PD-1 inhibitor *** SUMMARY The patient was a 27-year-old man who complained of enlarged right-sided cervical lymph nodes and progressive pain aggravation of the right shoulder over the past 3 mo before *** analysis of lymph node biopsy was suggestive of *** patient experienced failure of eight lines of therapy,including multiple cycles of chemotherapy,PD-1 blockade,and anti-CD47 antibody ***-enhanced CT showed that the tumors of the chest and abdomen significantly shrunk or disappeared after three cycles of treatment with decitabine plus *** patient had been followed for 11.5 mo until March 2,2021,and no progressive enlargement of the tumor was *** The strategy of combining low-dose decitabine with tislelizumab could reverse the resistance to PD-1 inhibitors in patients with heavily pretreated relapsed/refractory *** therapeutic effect of this strategy needs to be further assessed.

关键词： Immunotherapy Hypomethylating agent Classical Hodgkin lymphoma Survival Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma

引用

Chinese Journal of Cancer 2012年第7期31卷 348-353页

作者： Zhi-Tao Ying Wen Zheng Xiao-Pei Wang Yan Xie Mei-Feng Tu Ning-Jing Lin Ling-Yan Ping Wei-Ping Liu Li-Juan Deng Chen Zhang Jun Zhu Yu-Qin Song Key laboratory of Carcinogenesis and translational research(Ministry of Education) Lymphoma DepartmentPeking University Cancer Hospital&InstituteBeijing 100142P.R.China

Mantle cell lymphoma(MCL), a special type of non-Hodgkin's lymphoma, is incurable through conventional treatment. This study aimed to analyze the clinical features, therapeutic responses, and prognosis of patients with MCL. Clinical data of 30 patients with MCL treated in our hospital between April 2006 and July 2011 were analyzed. Eighteen patients were treated with CHOP plus rituximab (R-CHOP) regimen, 12 underwent conventional chemotherapy. The median age of the 30 patients was 58 years, 23 were men, all patients had Cyclin D1 overexpression, 29 (96.7%) had advanced disease, 11 (36.7%) had bone marrow involvement, 9 (30.0%) had gastrointestinal involvement, and 15 (50.0%) had splenomegaly. The complete response(CR) rate and overall response rate(ORR) were significantly higher in patients undergoing R-CHOP immunochemotherapy than in those undergoing conventional chemotherapy (38.9% vs. 16.7%, P = 0.187; 72.2% vs. 41.4%, P = 0.098). The difference of 2-year overall survival rate between the two groups was not significant (P = 0.807) due to the short follow-up time. The 2-year progression-free survival (PFS) rate was higher in R-CHOP group than in conventional chemotherapy group (53% vs. 25%, P = 0.083), and was higher in patients with a lower mantle cell lymphoma international prognostic index (MIPI) (51% for MIPI 0-3, 33% for MIPI 4-5, and 0% for MIPI 6-11, P = 0.059). Most patients with MCL were elderly; in an advanced stage; showed a male predominance; and usually had bone marrow involvement, gastrointestinal involvement, or splenomegaly. R-CHOP regimen could improve the CR rate and ORR of MCL patients. MIPI can be a new prognostic index for predicting the prognosis of advanced MCL.

关键词：临床特征淋巴瘤反应率患者治疗预后细胞 Cyclin

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Synchronous breast cancer and breast lymphoma:two case reports and literature review

引用

Chinese Journal of Cancer research 2014年第3期26卷 355-359页

作者： Jia Zhong Lijun Di Wen Zheng Key laboratory of Carcinogenesis and translational research (Ministry of Education) Department of Thoracic Medical OncologyPeking University Cancer Hospital & Institute Key laboratory of Carcinogenesis and translational research (Ministry of Education) Department of Breast Medical OncologyPeking University Cancer Hospital & Institute Key laboratory of Carcinogenesis and translational research (Ministry of Education) Department of LymphomaPeking University Cancer Hospital & Institute

Synchronous breast cancer and breast lymphoma are rare. It is of high rate of misdiagnosis in clinical practice. Here we present two cases with this presentation. They are both middle-aged women, with stage I invasive ductal carcinoma of the breast. One patient happened to have primary breast lymphoma （PBL）; the other was secondary breast lymphoma （SBL）. Their pathology and immunohistochemistry （IHC） findings supported the diagnosis of multiple primary carcinoma. Both patients had a surgery. Then they both received CHOP regime chemotherapy and subsequent endocrine therapy.

关键词： Breast cancer breast lymphoma synchronous multiple primary carcinoma treatment

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives

引用

Chinese Journal of Cancer research 2020年第3期32卷 303-318页

作者： Ningjing Lin Yuqin Song Jun Zhu Key laboratory of Carcinogenesis and translational research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China

Classical Hodgkin lymphoma(cHL) has been identified with universal genetic alterations of chromosome 9p24.1,which contains PD-L1/PD-L2 *** amplification of 9p24.1 is associated with the increased expression of PDL1 and PD-L2 on RS cells, which promotes their immune evasion, and subsequently makes cHL sensitive to PD-1 *** PD-1 inhibitors have shown significant efficacies with overall response rate(ORR) of 70%-90% in relapse/refractory(r/r) cHL and have acquired the approvals for this ***, more and more studies are conducted to investigate PD-1 blockade in earlier disease course and in combination with neo-agents or *** cHL, non-Hodgkin lymphoma(NHL) consists of numerous subtypes harboring highly biological *** a few subtypes have been shown to have genetic alteration of 9p24.1 including primary mediastinal B cell lymphoma(PMBL), gray zone lymphoma(GZL) with features intermediate between diffuse large B cell lymphoma(DLBCL) and cHL, primary central nervous system lymphoma(PCNSL) and primary testicular lymphoma(PTL).Epstein-Barr virus(EBV)-associated lymphomas have a virally mediated overexpression of PD-L1, also making them sensitive to PD-1 ***, PD-1 inhibitors are less effective in most r/r NHL than in r/r *** understanding of the biological features of NHL and immune checkpoint inhibitors(ICPi) combined therapy is the research focus in the *** this review, we outlined the recent progress of ICPi in lymphoma originating from clinical studies.

关键词： Immunotherapy immune checkpoint inhibitor PD-1 blockade Hodgkin lymphoma non-Hodgkin lymphoma

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The Incidence of lymphoma in Beijing:Comparing Results from MIS-CASS(2019)and Beijing Cancer Registry(2017)

引用

China CDC weekly 2021年第52期3卷 1118-1125,I0001页

作者： Hongrui Tian Weiping Liu Yuqin Song Lan Mi Zhen Liu Mengfei Liu Chuanhai Guo Fangfang Liu Ying Liu Yaqi Pan Jun Zhu Zhonghu He Yang Ke Key laboratory of Carcinogenesis and translational research(Ministry of Education/Beijing) Laboratory of GeneticsPeking University Cancer Hospital&InstituteBeijingChina Key laboratory of Carcinogenesis and translational research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijingChina.

Introduction:This study aimed to evaluate the performance of the Medical-Insurance-System-based Cancer Surveillance System(MIS-CASS)in estimating cancer incidence by comparing the results with the Beijing Cancer Registry(BCR),which is one of the highest-quality population-based cancer registries in ***:Using lymphoma as an example,we extracted relevant claims data from the administrative systems of medical insurance in Beijing(2012–2020)and estimated the most current lymphoma incidence in Beijing(2019)using a standard data processing *** absolute number of new cases,crude incidence rate,and age-standardized incidence rate of lymphoma were compared with the latest data reported by the BCR(2017).Results:Both lymphoma incidence rates and age distribution of new cases estimated based on MISCASS were similar to the BCR data(crude incidence rate:9.8/100,000 vs.10.6/100,000).However,because MIS-CASS included more designated hospitals and covered a larger local stationary population irrespective of household registration(hukou),the absolute number of incident lymphoma cases identified by MIS-CASS was 39.1%higher than that reported by the BCR(2,002 vs.1,439).Conclusions:The MIS-CASS approach reflected the actual cancer burden in a more complete and timely manner as compared with the current BCR,providing new insights for improving cancer surveillance strategies in China.

关键词： CASS Registry absolute

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：